ClinConnect ClinConnect Logo
Search / Trial NCT06804278

Role of Spectral CT in the Diagnosis of Myocarditis/MINOCA in Patients Undergoing cardioCT Investigations for Acute Chest Pain

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 29, 2025

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how a special type of CT scan, called Spectral CT, can help diagnose conditions like myocarditis (inflammation of the heart muscle) and MINOCA (myocardial infarction with no obstructive coronary arteries) in patients who come to the hospital with chest pain. The study focuses on patients who may not have clear signs of heart disease based on their initial tests, like an ECG or troponin levels, which are used to check for heart problems. By using the Spectral CT technology, researchers hope to find out whether it can help identify other causes of chest pain and any damage to the heart muscle itself.

To participate in this trial, you must be at least 18 years old and have been experiencing acute chest pain with a low or moderate chance of having a blocked artery. It's important that your initial tests (ECG and troponin) don't provide clear answers. If you decide to take part, you will undergo the Spectral CT scan, which is a safe and advanced imaging technique. However, there are some reasons you might not be eligible, such as being pregnant or having certain kidney problems. If you have any questions about the trial or your eligibility, the research team will be happy to help you understand more.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age greater than or equal to 18 years;
  • patients with acute chest pain and indication for triple-rule-out CT or coronary CT examination, i.e. low/intermediate probability of acute coronary artery disease, ECG and/or troponin not diagnostic or altered;
  • Obtaining informed consent
  • Exclusion Criteria:
  • Absolute contraindications to CT examination and/or iodinated mdc administration (i.e. pregnancy, severe renal impairment in non-dialysis patients with GFR \< 15-30 ml/min/1.73m2 );
  • CT examinations that do not allow diagnostic information to be provided because they are assessed as quality too scarce and not interpretable (affected by artifacts such as motion artifacts)

About Irccs Azienda Ospedaliero Universitaria Di Bologna

IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.

Locations

Bologna, , Italy

Patients applied

0 patients applied

Trial Officials

Vincenzo Russo, MD

Principal Investigator

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported